<DOC>
	<DOCNO>NCT03051243</DOCNO>
	<brief_summary>Prospective , open label , randomize study . A total 60 admit patient 18 85 year old known history DM 3 month average two consecutive blood glucose level 180 mg/dl ( stop previous oral antidiabetic insulin admission ) enrol Patient randomize 1:1 ratio two treatment group regimens- linagliptin ( trajenta ) daily combine basal insulin bed time ( glargine Lantus ; sanofi ) basal bolus insulin glargine daily glulisine ( Apidra ; sanifi ) meal . Patient discharge accord discharge protocol . Follow-up visit take place 3 6 month post discharge .</brief_summary>
	<brief_title>Safety Efficiency Linagliptin ( Trajenta ) Setting Internal Medicine Department</brief_title>
	<detailed_description>patient linagliptin plus basal insulin receive linagliptin single dose 5 mg/day , start total daily dose ( TDD ) glargine 0.3 units/kg/day , patient &gt; 70 year age and/or serum creatinine &gt; 2.0 mg/dL receive start TDD 0.15 units/kg . Patient basal bolus group start TDD 0.5 units/kg divide half insulin glargine daily half insulin glulisine meal . In patient &gt; 70 year age and/or serum creatinine &gt; 2.0 mg/dL , start TDD reduce 0.3 units/kg . The result BG value measure 2 hour pre meal glucose , bedtime glucose , mean daily BG first day hospital , HbA1c measure first day hospitalization . Patient pre-meal bed time blood glucose level 180 mg/dl receive correctional dos short act insulin base glucose level follow- 180-250mg/dl 2 unit insulin , 250-300 mg/dl 3 unit insulin , 350-400 4 unit insulin . Hypoglycemic event shall document well . In case treatment failure , define average blood glucose level two consecutive measurement 240 mg/dl , patient 's treatment change basal base regimen.Patient pre-meal bed time blood glucose level 180 mg/dl receive correctional dos short act insulin base glucose level follow- 180-250mg/dl 2 unit insulin , 250-300 mg/dl 3 unit insulin , 350-400 4 unit insulin . Hypoglycemic event shall document well . In case treatment failure , define average blood glucose level two consecutive measurement 240 mg/dl , patient 's treatment change basal base regimen . Patient discharge accord discharge protocol . Follow-up visit take place 3 6 month post discharge . Patients instructed measure record BG level ( pre meal glucose , bedtime glucose , mean daily BG ) three day follow-ups visit .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male &amp; female patient Known history DM 3 month randomization . Hospital admission due blood glucose level range 180400 mg/dl . Average two consecutive blood glucose level 180 mg/dl . Age 18 85 year old . Home treatment diet alone , combination oral antidiabetic agent , insulin therapy daily dose &lt; 0.4 units/kg . BG &gt; 400 mg/dl period randomization . Prior history hyperglycemic crisis . Have hyperglycemia without history diabetes . Patient expect ICU admission cardiac surgery . A history pancreatitis , active gallbladder disease , Corticosteroid therapy hepatic disease . Impaired renal function ( glomerular filtration rate [ GFR ] &lt; 30 mL/min serum creatinine â‰¥3.0 mg/dL ) . History diabetic ketoacidosis . Pregnancy . Inability give inform consent ( poor mental status ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>